NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial.

MLA

Sosa, Saily, et al. “NeuroEPO plus (NeuralCIM®) in Mild-to-Moderate Alzheimer’s Clinical Syndrome: The ATHENEA Randomized Clinical Trial.” Alzheimer’s Research & Therapy, vol. 15, no. 1, Dec. 2023, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s13195-023-01356-w.

APA

Sosa, S., Bringas, G., Urrutia, N., Peñalver, A. I., López, D., González, E., Fernández, A., Hernández, Z. M., Viña, A., Peña, Y., Batista, J. F., Valenzuela, C., León, K., Crombet, T., Rodríguez, T., Pérez, L., on behalf of the ATHENEA Investigators, Álvarez, Y., Rodríguez, M., & Vázquez, N. (2023). NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial. Alzheimer’s Research & Therapy, 15(1), 1–15. https://doi.org/10.1186/s13195-023-01356-w

Chicago

Sosa, Saily, Giosmany Bringas, Nelky Urrutia, Ana Ivis Peñalver, Danay López, Evelio González, Ana Fernández, et al. 2023. “NeuroEPO plus (NeuralCIM®) in Mild-to-Moderate Alzheimer’s Clinical Syndrome: The ATHENEA Randomized Clinical Trial.” Alzheimer’s Research & Therapy 15 (1): 1–15. doi:10.1186/s13195-023-01356-w.